Digest Réseau Comment ça marche
Réseau
/
Sociétés
Fo
Non vérifié

Forlong Biotechnology

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

12 communiqués de presse

Voir tous les communiqués de presse
04/08/2026
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Forlong Biotechnology Announces Approval to Initiate Phase I Clinical Trial of FL115 (IL-15 Superagonist) Subcutaneous Injection in Australia
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
03/08/2026
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Forlong Biotechnology Announces Successful Completion of GMP Pivotal Batch Production for FL115 (IL-15 Superagonist), Ready to Support Upcoming Phase III Clinical Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
27/05/2026
Événements
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Forlong Announces Completion of Phase I Clinical Studies of FL115 Monotherapy (IV): Disease Control for 3 Heavily-pretreated Patients with Advanced Solid Tumors over 12 Months
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
19/05/2026
Oncologie
Associations/Professionnels
Santé
Finance
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Industrie
Forlong Raises Approximately 120 Million RMB in Series Pre-B Financing to Advance its IL-15 and IL-18 Pipeline
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
21/04/2026
Expos
Analyse de marché
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé Publique
Santé
Médecine - Divers
Forlong Biotechnology to Present Clinical Data from the First-in-human Study for FL115 (IL-15 Superagonist) in US Patients with Advanced Solid Tumors at 2026 ASCO Annual Meeting
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
15/04/2026
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
17/03/2026
Événements
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
07/01/2026
Événements
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
30/10/2025
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Événements
Industrie
Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0
30/10/2025
Événements
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)
Source
Forlong Biotechnology
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0